Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elotuzumab, Iberdomide, and Dexamethasone Post Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma
NCT06518551Phase 1Recruiting
- Start
- Nov 2024
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of iberdomide in multiple myeloma (MM) (2 arms). Primary endpoints: Number of Participants Experiencing Dose Limiting Toxicity at 4 weeks and Maximum Tolerated Dose at 4 weeks. Started Nov 2024; status: recruiting.
02
Drugs
iberdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT06518551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06518551.